Evidence map›Paper›PMID 39622823›Full record

Trial reportNature communications2024

PET-CT outcomes from a randomised controlled trial of rosuvastatin as an adjunct to standard tuberculosis treatment.

Gail B Cross, Intan P Sari, Sarah M Burkill, Chee Woei Yap, Han Nguyen, Do Quyet, Victoria B Dalay, Emmanuel Gutierrez, Vincent M Balanag, Randy J Castillo and 4 more

Registry-linked trialAbstract readRandomized Controlled TrialClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04504851 (Rosuvastatin Evaluation as a Tuberculosis Treatment Adjunct), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04504851 phase2unknown statusnot on this map

Rosuvastatin Evaluation as a Tuberculosis Treatment Adjunct

TypeinterventionalSponsorNational University Hospital, SingaporeRan2020 to 2021Enrolled154ConditionsPulmonary TuberculosisArmsRosuvastatin 10mg, Rifampicin, Isoniazid, Pyrazinamide, Ethambutol
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Gail B CrossNational University Hospital, Department of Medicine, Singapore, Singapore. gail.cross@burnet.edu.au.ORCID 0000-0001-5116-9576
Intan P SariNational University Hospital, Department of Medicine, Singapore, Singapore.ORCID 0000-0003-2548-9378
Sarah M BurkillSingapore Clinical Research Institute, Singapore, Singapore.
Chee Woei YapNational University Health Systems, Department of Diagnostic Imaging, Singapore, Singapore.
Han NguyenVietnam Military Medical University, Respiratory Medicine, Hanoi, Viet Nam.ORCID 0000-0001-5541-8322
Do QuyetVietnam Military Medical University, Respiratory Medicine, Hanoi, Viet Nam.
Victoria B DalayDe La Salle Medical and Health Sciences Institute, Cavite, Philippines.
Emmanuel GutierrezDe La Salle Medical and Health Sciences Institute, Cavite, Philippines.
Vincent M BalanagLung Centre of the Philippines, Quezon City, Philippines.
Randy J CastilloLung Centre of the Philippines, Quezon City, Philippines.
Christina C ChangMonash University, Central Clinical School, Melbourne, Australia.ORCID 0000-0003-0109-0725
Anthony D KelleherKirby Institute, University of New South Wales, Sydney, Australia.ORCID 0000-0002-0009-3337
Jim O'DohertyNational University of Singapore, Clinical Imaging Research Centre, Singapore, Singapore.ORCID 0000-0003-2989-4485
Nicholas I PatonNational University Hospital, Department of Medicine, Singapore, Singapore.

Funding

MOH | National Medical Research Council (NMRC) CIRG16nov049MOH | National Medical Research Council (NMRC) NMRC/CIRG/1322/2012
6 · The paper itself

Abstract

Adjunctive rosuvastatin for rifampicin-susceptible pulmonary tuberculosis (rs-PTB) shows no effect on microbiological or radiological outcomes in a phase IIb randomised, controlled trial (NCT04504851). We explore the impact of adjunctive rosuvastatin on 18F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) imaging in a sub-study of 24 participants. Changes in standardised uptake value (SUVmax, SUVmean), Total Metabolic Volume, (TMV), Total Lesion Glycolysis (TLG), cavity diameter and volume, between week 0 and week 8 post-randomisation, are evaluated. Here we show no evidence of difference in the reduction in TLG [median 65.8% for the rosuvastatin group (Q1, Q3 38.6, 94.5) vs 64.3% for standard tuberculosis treatment group (Q1, Q3 -20.0, 81.7), P = 0.32], reduction in cavity volume on CT [median 3.2 cm

Indexed as

Antitubercular AgentsFluorodeoxyglucose F18Positron Emission Tomography Computed TomographyRosuvastatin CalciumTuberculosis, PulmonaryAdultFemaleHumansMaleMiddle AgedRifampinTreatment OutcomeAntitubercular AgentsFluorodeoxyglucose F18RifampinRosuvastatin Calcium

Identifiers

PMID39622823
PMCPMC11611914

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.